Acquired resistance to anti-EGFR therapy in colorectal cancer

Acquired resistance to anti-EGFR therapy in colorectal cancer

Overcoming acquired resistance to targeted therapy in colorectal cancerПодробнее

Overcoming acquired resistance to targeted therapy in colorectal cancer

Winship Grand Rounds: August 25, 2021 - John Strickler, MDПодробнее

Winship Grand Rounds: August 25, 2021 - John Strickler, MD

Lung Cancer Update | 2022 Metro Denver Oncology Nursing Society ConferenceПодробнее

Lung Cancer Update | 2022 Metro Denver Oncology Nursing Society Conference

EGFR TKI Resistance: Progress and ChallengesПодробнее

EGFR TKI Resistance: Progress and Challenges

Anti-EGFR rechallenge therapy with or without trametinib in addition to panitumumab in advanced CRCПодробнее

Anti-EGFR rechallenge therapy with or without trametinib in addition to panitumumab in advanced CRC

Acquired resistance to EGFR antibodiesПодробнее

Acquired resistance to EGFR antibodies

Colorectal Cancer with acquired resistance to EGFR antibodies: How to manage?Подробнее

Colorectal Cancer with acquired resistance to EGFR antibodies: How to manage?

Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhDПодробнее

Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhD

Detecting resistance to EGFR rechallenge in RAS/RAF WT CRCПодробнее

Detecting resistance to EGFR rechallenge in RAS/RAF WT CRC

Role of Genomics in Identifying Biomarkers for Response and Resistance to Anti-Cancer ImmunotherapyПодробнее

Role of Genomics in Identifying Biomarkers for Response and Resistance to Anti-Cancer Immunotherapy